Your browser doesn't support javascript.
loading
Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities.
Schmitt, E; Cimoli, G; Steyaert, A; Bertrand, R.
Affiliation
  • Schmitt E; Hospital Research Center of University of Montreal (CHUM), Montreal Cancer Institute, Quebec, Canada.
Exp Cell Res ; 240(1): 107-21, 1998 Apr 10.
Article in En | MEDLINE | ID: mdl-9570926
ABSTRACT
Using an episomal eucaryotic expression vector, we derived three stable transfected human leukemic U-937 variant lines showing differential expression of the Bcl-xL protein. Preventive effect of Bcl-xL on cell death induced by various concentrations of camptothecin (DNA topoisomerase I inhibitor; CPT) was observed in the three lines with most pronounced effect in cells containing the highest level of Bcl-xL expression. These results show that increased cell death protection by Bcl-xL is correlated with its level of expression. The extent of DNA strand break formation and DNA synthesis inhibition following CPT treatments was similar in control and transfected U-937 cells, suggesting that Bcl-xL acts downstream of CPT-DNA topoisomerase I-mediated DNA strand breaks. Modulation of cell death by Bcl-xL was also observed in cells treated with etoposide, vinblastine, paclitaxel, and cisplatinum (II) diammine dichloride. To define whether Bcl-xL functions downstream or upstream of apoptogenic proteolytic cascade activation, we compared kinetics of DNA fragmentation in treated cells with kinetics of caspase 1-like, caspase 3-like, and N-tosyl-L-phenylalanylchloromethyl ketone (TPCK)-sensitive activities. In CPT-treated U-937 cells, caspase 3-like and TPCK-sensitive activities promoting DNA fragmentation in a cell-free system were detected much more rapidly in extracts obtained from CPT-treated U-937 cells compared to those obtained from CPT-treated U-937-Bcl-xL variant cells. These results suggest that Bcl-xL delays their activation that correlates with the occurrence of DNA fragmentation. Addition of recombinant Bcl-xL in extracts containing DEVDase and TPCK-sensitive activities did not inhibit these activities, suggesting that Bcl-xL acts primarily upstream of their activation in the apoptotic process. Taken together, these results suggest that Bcl-xL is a primary checkpoint that can block or delay transmission of cell death signals emerging from DNA damage and prevents activation of an apoptogenic proteolytic cascade.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Peptide Hydrolases / Camptothecin / Proto-Oncogene Proteins c-bcl-2 / DNA Fragmentation / Antineoplastic Agents, Phytogenic Limits: Humans Language: En Journal: Exp Cell Res Year: 1998 Type: Article Affiliation country: Canada
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Peptide Hydrolases / Camptothecin / Proto-Oncogene Proteins c-bcl-2 / DNA Fragmentation / Antineoplastic Agents, Phytogenic Limits: Humans Language: En Journal: Exp Cell Res Year: 1998 Type: Article Affiliation country: Canada